Communiqués VACY AS Oslo Bors

Actions

VACC

NO0010714785

Cours en clôture Oslo Bors Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^PTS	-.--%		-.--%	-.--%

20/06	Nykode Therapeutics annonce des mises à jour sur sa plateforme de vaccins inversés lors de la réunion FOCIS 2024	CI
11/06	Nykode Therapeutics ASA annonce que le vaccin anti-cancer ARNm-LNP démontre une efficacité supérieure	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nykode Therapeutics : Grant of share options	01/07	PU
Nykode Therapeutics : Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	20/06	PU
Nykode Therapeutics : presentation from ABGSC Seminar on Autoimmunity, Transplantation & Inflammation	11/06	PU
Nykode Therapeutics : Q1 2024 Financial Results – presentation	14/05	PU
Nykode Therapeutics : Q1 2024 Financial Results	14/05	PU
Nykode Therapeutics : reports Q1 2024 Financial Results	14/05	PU
Nykode Therapeutics : Remuneration Report 2023	19/04	PU
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider	27/10/23	AQ
Nykode Therapeutics : 2Q 2023 Financial Results – presentation	23/08/23	PU
Nykode Therapeutics : ABGSC Life Science Summit 30-31 May 2023 – presentation	07/06/23	PU
Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer	01/06/23	GL
Nykode Therapeutics to Present at Jefferies Healthcare Conference	30/05/23	GL
Nykode Therapeutics : 1Q 2023 Financial Results – presentation	12/05/23	PU
Nykode Therapeutics : Nomination Committee Proposal	20/04/23	PU
Nykode Therapeutics : Final Results from the Phase 2 VB-C-02 trial – presentation	19/04/23	PU
Nykode Therapeutics : ESG Report 2022	19/04/23	PU
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer	18/04/23	GL
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer	18/04/23	AQ
Nykode Therapeutics : Remuneration Guidelines	14/04/23	PU
Nykode Therapeutics : 4Q 2022 Financial Results – presentation	28/02/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués VACY AS Oslo Bors

Actions

VACC

NO0010714785

Communiqués

Filtres